Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours

Por Cianfrocca, M E, Kimmel, K A, Gallo, J, Cardoso, T, Brown, M M, Hudes, G, Lewis, N, Weiner, L, Lam, G N, Brown, S C, Shaw, D E, Mazar, A P, Cohen, R B
Publicado em 2006